Growth hormone-releasing hormone (GHRH) analogs are one of the most frequently studied peptide classes in endocrine receptor research. Two compounds come up again and again in the literature: Tesamorelin and Sermorelin. Both bind the same receptor, the GHRH receptor (GHRH-R) on pituitary somatotrophs, yet they differ significantly in molecular structure, enzymatic stability, regulatory history, and the kind of literature built around each.
This article summarizes what the published literature says about each compound's chemistry, receptor pharmacology and laboratory handling, so researchers can choose a tool compound on the basis of structure and documentation rather than marketing.
For research use only. Not for human consumption.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of endogenous human GHRH, specifically the full 44-amino-acid sequence modified with a trans-3-hexenoic acid group at its N-terminus. This modification blocks the N-terminal site where the enzyme dipeptidyl peptidase IV (DPP-IV) cleaves native GHRH, which makes tesamorelin considerably more resistant to enzymatic degradation than the unmodified sequence.
Molecular profile:
- Full name: (Trans-3-hexenoic acid)-GRF(1-44)-NH₂
- Molecular weight: 5,135.9 Da
- Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
- PubChem CID: 16137828
- Receptor pharmacology: Binds GHRH-R (Gαs-coupled) and activates the cAMP/PKA cascade in somatotroph cells
Regulatory status: tesamorelin is the active ingredient of an FDA-approved prescription drug product for one specific indication. That approval applies only to the finished drug product. Tesamorelin sold as a research peptide is not approved for human use and is supplied for in-vitro laboratory research only.
Tesamorelin is available from Excalibur Peptides for in-vitro laboratory research. A Certificate of Analysis is published for this product.
Key Literature Themes — Tesamorelin
The laboratory literature on tesamorelin and related GHRH analogs falls into a few clear themes:
- Structure-activity work: Studies of N-terminal modifications to GHRH examined how capping or substituting the first residues changes DPP-IV susceptibility while preserving receptor binding. The trans-3-hexenoyl group in tesamorelin comes out of that line of chemistry.
- Receptor signaling: Reviews of GHRH-R signaling describe coupling to Gαs, adenylyl cyclase activation and cAMP accumulation, together with kinase branches such as ERK/MAPK downstream (Mayo et al., Recent Prog Horm Res 1995, PMID 7740167; Mayo et al., Recent Prog Horm Res 2000, PMID 11036940).
- Analytical chemistry: As a 44-residue peptide carrying a lipophilic N-terminal group, tesamorelin is characterized by reverse-phase HPLC with shallow acetonitrile gradients and by electrospray mass spectrometry, where the multiply charged ion series is deconvoluted to confirm the intact mass.
- Stability studies: In-vitro incubations in plasma or with purified DPP-IV are used to compare the degradation rate of modified and unmodified GHRH sequences, typically monitored by HPLC or LC-MS over a time course.
- Pituitary cell models: Primary rat pituitary cell cultures and somatotroph-derived cell lines are used to measure GH secretion and cAMP accumulation in response to GHRH analogs, with somatostatin often included to examine inhibitory control.
What Is Sermorelin?
Sermorelin is a truncated synthetic GHRH analog corresponding to the first 29 amino acids of endogenous GHRH, designated GHRH(1-29)NH₂. Structure-activity studies established that this shorter fragment retains binding and signaling activity at the GHRH receptor, but it lacks the N-terminal modification present in tesamorelin.
Molecular profile:
- Full name: GHRH(1-29)-NH₂
- Amino acids: 29 (vs. 44 in native GHRH, vs. 44 plus an N-terminal modification in Tesamorelin)
- Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
- Molecular weight: approximately 3,357.9 Da
- Receptor pharmacology: Same Gαs/cAMP/PKA pathway as Tesamorelin in somatotroph cells
Regulatory status: sermorelin was previously approved in the United States as a diagnostic agent, but that product was withdrawn in 2008 for commercial reasons. Sermorelin sold as a research chemical is not approved for human use. It remains one of the most frequently cited GHRH fragments in the structure-activity literature.
Key Literature Themes — Sermorelin
- Minimal active fragment: GHRH(1-29)NH₂ is widely used as the reference fragment in structure-activity work, because it is the shortest sequence that retains full receptor activity in pituitary cell assays.
- Receptor signaling: Reviews of GHRH receptor biology cover sermorelin's receptor binding profile alongside native GHRH and later synthetic analogs (Mayo et al., Recent Prog Horm Res 1995, PMID 7740167).
- Downstream cascades: Reviews of GHRH receptor signaling in the somatotroph describe downstream pathways that apply to both sermorelin and tesamorelin (Mayo et al., Recent Prog Horm Res 2000, PMID 11036940).
Tesamorelin vs. Sermorelin: Direct Comparison
| Parameter | Tesamorelin | Sermorelin |
|---|---|---|
| Amino acids | 44 (full GHRH + N-terminal mod) | 29 (truncated fragment) |
| Structural modification | Trans-3-hexenoic acid at N-terminus | None — native fragment |
| Receptor | GHRH-R (full agonist) | GHRH-R (full agonist) |
| DPP-IV susceptibility | Reduced (N-terminal hexenoyl group blocks cleavage) | High (unmodified N-terminus) |
| Regulatory status | Active ingredient of an FDA-approved drug product for one indication; research material not approved for human use | Former diagnostic approval withdrawn 2008; research material not approved for human use |
| Molecular weight | 5,135.9 Da | ~3,357.9 Da |
| Molecular formula | C₂₂₁H₃₆₆N₇₂O₆₇S | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Signaling pathway | Gαs → adenylyl cyclase → cAMP/PKA | Gαs → adenylyl cyclase → cAMP/PKA |
| Common in-vitro readouts | cAMP accumulation, CREB reporter, GH secretion from pituitary cells | cAMP accumulation, CREB reporter, GH secretion from pituitary cells |
| Typical analytical methods | RP-HPLC, ESI-MS (deconvoluted intact mass) | RP-HPLC, ESI-MS |
Receptor Pharmacology: Where They're the Same
Both compounds act through the same signaling cascade in somatotroph cells:
- Bind GHRH-R on anterior pituitary somatotrophs
- Activate Gαs protein → adenylyl cyclase stimulation
- Raise intracellular cAMP → PKA activation
- Downstream: kinase cascades such as ERK/MAPK extend the signal
- Readout: GH secretion from somatotroph cultures, which in animal physiology follows a pulsatile pattern shaped by hypothalamic somatostatin
In animal physiology, GHRH-receptor signaling operates inside the hypothalamic-pituitary axis and remains subject to feedback inhibition by somatostatin. This is why GHRH analogs are used as research tools for studying how the axis is regulated, and why somatostatin is a standard co-treatment in pituitary cell assays.
Enzymatic Stability: Where They Diverge
The N-terminal hexenoic acid modification in tesamorelin is the structural key to understanding why these compounds behave differently in experimental systems.
Tesamorelin: The modification confers resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, which is the primary degradation pathway for unmodified GHRH peptides. DPP-IV removes the N-terminal Tyr-Ala dipeptide from native GHRH, producing a fragment with greatly reduced receptor activity. Capping the N-terminus blocks this step.
Sermorelin: As an unmodified GHRH fragment, sermorelin is susceptible to rapid DPP-IV cleavage, as well as to other serum proteases that act on internal sites. In serum-containing culture media, this means its effective concentration falls faster than that of tesamorelin over the course of an experiment.
From an experimental design standpoint, both compounds activate the same receptor, but the difference in enzymatic stability affects how long a given concentration is maintained in media containing serum or tissue extracts. Researchers comparing the two should run stability controls, for example by sampling the media at several time points and measuring intact peptide by LC-MS.
CJC-1295 and Ipamorelin: Where Do They Fit?
Two other compounds frequently appear alongside tesamorelin and sermorelin in the literature:
CJC-1295 (with DAC, Drug Affinity Complex): A modified GHRH(1-29) analog carrying a reactive maleimide linker that forms a covalent bond with albumin. This albumin-binding chemistry greatly extends its persistence compared with unmodified GHRH fragments (Jetté et al., Endocrinology 2005, PMID 15817669). CJC-1295 is a useful example of how conjugation chemistry, rather than sequence modification alone, can change the stability profile of a peptide.
Ipamorelin: A synthetic pentapeptide growth hormone secretagogue that acts at the ghrelin receptor (GHS-R1a) rather than GHRH-R. Animal pharmacology studies characterized its selectivity for GH release relative to ACTH, cortisol and prolactin (Raun et al., Eur J Endocrinol 1998, PMID 9849822).
Because GHRH analogs and GHS-R1a agonists act on separate receptors, they are sometimes examined together in pituitary cell and animal models to study how the two receptor systems interact. For more on that pairing, see our tesamorelin and ipamorelin research article.
How the Published Literature Differs
Tesamorelin has been through a full regulatory development program, so its literature is larger and more recent. For laboratory researchers, the parts most relevant to bench work are:
- Structure-activity and stability chemistry of the N-terminal modification
- Receptor pharmacology at GHRH-R
- Analytical characterization of a modified 44-residue peptide
- Published physicochemical data (formula, molecular weight, PubChem record)
Sermorelin's literature is older and centers on:
- Structure-activity work defining GHRH(1-29) as the minimal active fragment
- Receptor binding studies in pituitary cell preparations
- Comparative work with native GHRH and later analogs
- Historical data from the 1980s–2000s
Neither body of literature supports any use of research material in humans. For laboratory researchers, the practical question is usually which structure suits the assay design.
Practical Considerations for Research
Stability: Tesamorelin's structural modification makes it more stable against DPP-IV compared with unmodified GHRH fragments. Sermorelin's shorter, unmodified structure is more susceptible to degradation in serum-containing media.
Assay timing: Because sermorelin is degraded faster in serum-containing media, sampling time points and media changes should be chosen with that in mind, and stability controls should be run alongside receptor assays.
Somatostatin co-treatment: Both compounds remain subject to somatostatin-mediated inhibition in pituitary cell models. Including somatostatin in the design allows researchers to examine the inhibitory arm of GH regulation alongside GHRH-R activation.
Receptor dependence: Both compounds require GHRH-R expression to produce a response. Cell lines that do not express the receptor are a useful negative control, and receptor-transfected lines allow the two analogs to be compared under identical conditions.
Storage and handling: Both peptides are handled as lyophilized powders, kept cold and protected from moisture and light; Excalibur Peptides lists its tesamorelin for storage at 2–8 °C. Solutions for in-vitro work should be prepared fresh or divided into single-use aliquots and stored frozen.
Summary
Tesamorelin and sermorelin share the same fundamental receptor pharmacology, GHRH receptor agonism leading to cAMP signaling and GH secretion in somatotroph cells, but differ in molecular architecture, enzymatic stability, literature depth, and regulatory history.
Tesamorelin may suit in-vitro designs where resistance to DPP-IV and a longer-lasting concentration in serum-containing media matter.
Sermorelin suits structure-activity work built around the minimal active GHRH fragment and a shorter, unmodified sequence.
Both are sold strictly for laboratory research, and neither research material is approved for human use.
Frequently Asked Questions
What is the main difference between tesamorelin and sermorelin?
Tesamorelin is a full 44-amino-acid GHRH analog with a synthetic N-terminal modification that increases its resistance to DPP-IV degradation. Sermorelin is a shorter 29-amino-acid fragment of GHRH without structural modifications. Both activate the GHRH receptor and the same cAMP signaling pathway, but tesamorelin is more stable against enzymatic cleavage and has a larger published literature.
Is tesamorelin FDA-approved?
Tesamorelin is the active ingredient of an FDA-approved prescription drug product for one specific indication. That approval does not cover research peptides: tesamorelin sold as a research chemical is not approved for human use and is supplied for in-vitro laboratory research only. Sermorelin was previously approved as a diagnostic agent, but that product was withdrawn in 2008 for commercial reasons.
Do tesamorelin and sermorelin work the same way?
Yes. Both bind the GHRH receptor on pituitary somatotrophs and activate the same Gαs/cAMP/PKA signaling cascade, which leads to growth hormone secretion in pituitary cell models. The receptor pharmacology is the same; the differences lie in enzymatic stability, molecular structure and literature depth.
How does the published literature on tesamorelin and sermorelin differ?
Tesamorelin has been through a full regulatory development program, so its literature is larger and more recent, including structure-activity, stability and analytical work on the N-terminal modification. Sermorelin's literature is older and centers on structure-activity studies that defined GHRH(1-29) as the minimal active fragment, largely from the 1980s to the early 2000s.
How should tesamorelin research material be stored?
Lyophilized tesamorelin should be stored at 2–8 °C, as listed on the product page, protected from moisture and light. Allow the vial to reach room temperature before opening, prepare solutions for in-vitro work fresh or divide them into single-use aliquots, and avoid repeated freezing and thawing.
Why are tesamorelin and sermorelin often discussed alongside ipamorelin?
Ipamorelin acts at the ghrelin receptor (GHS-R1a) rather than the GHRH receptor. Because the two receptor systems are separate, GHRH analogs and GHS-R1a agonists are each used in pituitary cell and animal models to study how the two pathways interact. Animal pharmacology studies characterized ipamorelin's selectivity for GH release relative to cortisol and prolactin (Raun et al., Eur J Endocrinol 1998, PMID 9849822).
Why is tesamorelin more resistant to enzymatic degradation than sermorelin?
Tesamorelin carries a trans-3-hexenoic acid group at its N-terminus, which blocks the site where DPP-IV cleaves native GHRH. Sermorelin has an unmodified N-terminus, so DPP-IV and other serum proteases degrade it more quickly in experimental systems.
Where can I source tesamorelin or sermorelin for research?
Excalibur Peptides supplies tesamorelin for in-vitro laboratory research, and a Certificate of Analysis is published for this product. Sermorelin is not currently listed in the catalog. All products are intended for research use only and are not approved for human use.
This article is for research and educational purposes only. The regulatory approval of a finished tesamorelin drug product does not extend to research peptides. The compounds discussed here are sold for in-vitro laboratory research only, are not approved for human use, and must not be administered to humans.
References: Mayo KE et al., Recent Prog Horm Res 1995 (PMID 7740167); Mayo KE et al., Recent Prog Horm Res 2000 (PMID 11036940); Jetté L et al., Endocrinology 2005 (PMID 15817669); Raun K et al., Eur J Endocrinol 1998 (PMID 9849822); PubChem CID 16137828 (tesamorelin).